A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours.
about
Advances in targeted and immunobased therapies for colorectal cancer in the genomic eraDual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal CancersPopulation Pharmacokinetics of Selumetinib and Its Metabolite N-desmethyl-selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low-Grade Gliomas.Molecular Checkpoint Decisions Made by Subverted Vascular Niche Transform Indolent Tumor Cells into Chemoresistant Cancer Stem CellsFluorescent-Antibody Targeting of Insulin-Like Growth Factor-1 Receptor Visualizes Metastatic Human Colon Cancer in Orthotopic Mouse Models.IGFBP2 modulates the chemoresistant phenotype in esophageal adenocarcinoma.The Effect of Diabetes Mellitus on Lung Cancer Prognosis: A PRISMA-compliant Meta-analysis of Cohort Studies.Type I insulin-like growth factor receptor signaling in hematological malignancies.A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors.IGF-binding protein 2 is a candidate target of therapeutic potential in cancer.Snail-Modulated MicroRNA 493 Forms a Negative Feedback Loop with the Insulin-Like Growth Factor 1 Receptor Pathway and Blocks TumorigenesisNovel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications.Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory.Picropodophyllin (PPP) is a potent rhabdomyosarcoma growth inhibitor both in vitro and in vivoCombining targeted therapeutics in the era of precision medicine.
P2860
Q26751344-966922DF-ECE3-43E0-BE2E-707982894CB1Q26781362-DE0285ED-F4F3-4472-83C0-2FA76A4939D1Q33729778-41CE81C8-3C91-4DBB-81CE-D4F1BB891CCAQ33872400-386DB896-B026-42F7-BE87-3F5ABDF6E97BQ35885302-255E1CFE-00B4-44F6-8F02-F43BC539F10BQ36413323-5964D451-6B85-447B-8F0A-103BF5199C0AQ37206482-430E88FA-9CC9-4F50-A801-BDAFD8D6B5D1Q37702186-6FD31CAC-7E70-4CC0-8FA8-CD2940E6DA65Q38393041-37FACC66-46C3-4968-A90F-0D40741AA05AQ38667847-53622B10-78A5-47B4-BCA5-801F7E07E86AQ38726530-9719DC1A-8458-474E-B045-EB80CA401D1CQ38794338-10FC1A23-02F6-45BD-9ABE-C66747D5A768Q38827897-5940E36A-6F61-49AD-AB0B-40A483DC3933Q41336735-F6995F4C-2904-40FD-9100-E3F002FB3B12Q42745856-821AD1AB-E13B-47AE-A8FE-C63E4E472A62
P2860
A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
A phase I trial of vertical in ...... or, in advanced solid tumours.
@ast
A phase I trial of vertical in ...... or, in advanced solid tumours.
@en
type
label
A phase I trial of vertical in ...... or, in advanced solid tumours.
@ast
A phase I trial of vertical in ...... or, in advanced solid tumours.
@en
prefLabel
A phase I trial of vertical in ...... or, in advanced solid tumours.
@ast
A phase I trial of vertical in ...... or, in advanced solid tumours.
@en
P2093
P2860
P356
P1476
A phase I trial of vertical in ...... or, in advanced solid tumours.
@en
P2093
D A Laheru
D Cosgrove
P2860
P2888
P356
10.1038/BJC.2014.515
P407
P577
2014-09-30T00:00:00Z
P5875
P6179
1050016464